

# Table of Contents

|   |     |
|---|-----|
| Myelodysplastic syndromes: State of the art pathology, diagnosis and management<br>P. FENAUX  | 307 |
| 1. The evolving challenge of therapy-related myeloid neoplasms<br>J. E. CHURPEK & R. A. LARSON  | 309 |
| 2. Occupational and environmental etiology of MDS<br>D. T. BOWEN  | 319 |
| 3. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?<br>T. BRAUN & P. FENAUX   | 327 |
| 4. Morphology, cytogenetics and classification of MDS<br>A. GIAGOUNIDIS & D. HAASE  | 337 |
| 5. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes<br>R. ITZYKSON, O. KOSMIDER & P. FENAUX  | 355 |
| 6. Deletion 5q MDS: Molecular and therapeutic implications<br>R. S. KOMROKJI, E. PADRON, B. L. EBERT & A. F. LIST   | 365 |
| 7. Refractory anemia with ring sideroblasts<br>L. MALCOVATI & M. CAZZOLA  | 377 |
| 8. Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?<br>R. ITZKSON, P. FENAUX & E. SOLARY   | 387 |
| 9. Erythropoiesis stimulating agents and other growth factors in low-risk MDS<br>E. HELLSTRÖM-LINDBERG & A. VAN DE LOOSDRECHT   | 401 |
| 10. Hypomethylating agents and chemotherapy in MDS<br>L. ADÈS & V. SANTINI  | 411 |
| 11. Allogeneic stem cell transplantation in MDS: How? When?<br>U. PLATZBECKER & G. MUFTI  | 421 |
| 12. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?<br>D. P. STEENSMA & N. GATTERMANN | 431 |